Red Blood Cell-Derived Vesicles for Nanoparticle Drug Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Nanoparticles used for drug delivery, such as superparamagnetic iron oxide nanoparticles, face challenges with low cellular internalization efficiency and potential toxicity, which limits their application in biomedicine, particularly for stem cell tracking and therapy.

Innovation Solution

The development of isolated red blood cell-derived vesicles (RDV) with diameters of up to 500 nanometers that can encapsulate substances like fluorophores, nucleic acids, and therapeutic agents, allowing them to enter cells without surface modification, including stem cells, and be tracked using MRI.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If superparamagnetic iron oxide nanoparticles are used for drug delivery and stem cell tracking, then cellular internalization efficiency is improved, but potential toxicity increases

Engineering Contradiction:

Improvecellular internalization efficiencyVSAvoidnanoparticle toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses red blood cell-derived vesicles as intermediary carriers that naturally internalize into cells through endocytosis, avoiding direct nanoparticle-cell contact that causes toxicity. The vesicles serve as a biocompatible mediator delivering therapeutic agents while maintaining cell viability and reducing harmful effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the size parameter of the vesicles to be within the nanoparticle range (smaller than 1 micron) to maintain cellular internalization efficiency while changing the material composition from synthetic nanoparticles to biodegradable red blood cell membranes, thereby reducing toxicity.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If nanoparticles are modified to improve cellular internalization, then internalization efficiency is improved, but potential hazards increase

Engineering Contradiction:

Improvecellular internalization efficiencyVSAvoidpotential hazards

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The red blood cell-derived vesicles utilize the cell's own endocytic machinery to internalize into target cells without requiring external modifications or surface conjugations. The vesicles self-assemble and are naturally taken up by cells through physiological endocytosis pathways, avoiding hazards associated with surface modifications.

Inventive Principle:

Principle #25Self-service

3Object-affected harmful factors

If red blood cells are used as carriers, then biocompatibility is improved, but cell size is too large for effective nanoparticle delivery

Engineering Contradiction:

ImprovebiocompatibilityVSAvoidcell size

Core Design Contradiction:

Object-affected harmful factorsVSLength of moving object

Solution Approach 1:

The patent segments the red blood cell into smaller vesicular structures (microvesicles, exosomes, or apoptotic bodies) that retain the biocompatible properties of the original cell membrane but are reduced in size to the nanoparticle range, enabling effective cellular internalization while maintaining biocompatibility.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts the essential biocompatible membrane properties from intact red blood cells and transfers them to smaller vesicular structures, separating the size constraint from the biocompatibility function. The extracted membrane components form vesicles that are both small enough for internalization and maintain the original cell's biocompatible characteristics.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

RDV effectively deliver encapsulated substances into cells, including stem cells, while maintaining biocompatibility, thus addressing the limitations of nanoparticle toxicity and internalization efficiency, and enabling safe and efficient drug delivery and tracking.

Implementation Method 1

The isolated RDV is capable of entering cells other than macrophages, and without any modification on the surface membrane thereof

Methodology Applied

Scientific EffectInternalization:

Implementation Method 2

superparamagnetic iron oxide (SPIO) nanoparticles have been recognized as a promising tool to intracellular labeling of cells for cellular magnetic resonance imaging (MRI)

Methodology Applied

Scientific EffectSuperparamagnetism: Superparamagnetism

Data Source

PatentUS8329161B2Red blood cell-derived vesicles as a nanoparticle drug delivery system

Publication Date: 2012.12.11 NATIONAL HEALTH RESEARCH INSTITUTE

AI summary

Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo.